Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Plavix does not affect overall risk of death in patients with heart disease.
November 11, 2015 Off

Plavix does not affect overall risk of death in patients with heart disease.

By Dino Mustafić

Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.

Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”
November 11, 2015 Off

Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”

By Dino Mustafić

Diplomat Pharmacy, NYSE-listed pharmaceutical company, will dispense Cotellic in combination with the BRAF inhibitor Zelboraf to treat patients with advanced melanoma that cannot be removed by surgery, or that has spread from the primary site.

November 11, 2015 Off

Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents

By Dino Mustafić

Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents.

Allergan submits Prior Approval Supplement for RESTASIS
November 11, 2015 Off

Allergan submits Prior Approval Supplement for RESTASIS

By Dino Mustafić

Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.

November 10, 2015 Off

Inaffit pulls back Natureal light and dark green capsules

By Dino Mustafić

Inaffit is voluntarily recalling all lots of Natureal light green and dark green capsules to the consumer level after FDA laboratory testing found Natureal to contain sibutramine.

November 10, 2015 Off

Zenobia recalls Ground Flax Seed Meal due to salmonella

By Dino Mustafić

Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.

Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
November 9, 2015 Off

Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo

By Dino Mustafić

Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…

Sanofi’s and Regeneron’s study shows improvements in signs and symptoms of rheumatoid arthritis
November 9, 2015 Off

Sanofi’s and Regeneron’s study shows improvements in signs and symptoms of rheumatoid arthritis

By Dino Mustafić

Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…

Cosentyx shows no further progression in joint damage in over 80% of PsA
November 9, 2015 Off

Cosentyx shows no further progression in joint damage in over 80% of PsA

By Dino Mustafić

Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…

Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission
November 9, 2015 Off

Investigational baricitinib superior to methotrexate monotherapy in achveing clinical remission

By Dino Mustafić

Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…

Posts pagination

Previous 1 … 3,586 3,587 3,588 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine